Multidrug-resistant Gram-negative bacteria: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 2: | Line 2: | ||
*[[Ceftolozane-tazobactam]] (Zerbaxa) |
*[[Ceftolozane-tazobactam]] (Zerbaxa) |
||
**May be better for multidrug-resistance [[Pseudomonas]] (or at least more experience with it) |
|||
* |
|||
*[[Ceftazidime-avibactam]]: available through Special Access Program |
*[[Ceftazidime-avibactam]]: available through Special Access Program |
||
**Adds coverage of some carbapenemases and AmpC |
|||
*[[Fosfomycin]] |
*[[Fosfomycin]] |
||
** |
** |
||
Revision as of 13:31, 26 August 2020
Management
- Ceftolozane-tazobactam (Zerbaxa)
- May be better for multidrug-resistance Pseudomonas (or at least more experience with it)
- Ceftazidime-avibactam: available through Special Access Program
- Adds coverage of some carbapenemases and AmpC
- Fosfomycin
- Colistin
- Cefiderocol: available through Special Access Program as well as preapproval by manufacturer
- Meropenem-vaborbactam: still awaiting Health Canada Drug Review
- Imipenem-relebactam (really imipenem-cilastatin-relebactam): still awaiting Health Canada Drug Review
References
- ^ A.-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D.L. Paterson, L.B. Rice, J. Stelling, M.J. Struelens, A. Vatopoulos, J.T. Weber, D.L. Monnet. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection. 2012;18(3):268-281. doi:10.1111/j.1469-0691.2011.03570.x.
